Published in Int J Cancer on May 15, 2006
Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget (2014) 0.88
TGF-β mediated DNA methylation in prostate cancer. Transl Androl Urol (2012) 0.85
XAF1 is frequently methylated in human esophageal cancer. World J Gastroenterol (2012) 0.84
Domain organization of XAF1 and the identification and characterization of XIAP(RING) -binding domain of XAF1. Protein Sci (2012) 0.81
XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. Proc Natl Acad Sci U S A (2014) 0.78
A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells. Gastric Cancer (2014) 0.76
Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget (2017) 0.75
Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding. Sci Rep (2015) 0.75
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol (2016) 2.94
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 2.32
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
An infectious disease of ducks caused by a newly emerged Tembusu virus strain in mainland China. Virology (2011) 2.05
Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 1.92
Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA (2006) 1.81
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis (2002) 1.68
Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int (2007) 1.61
Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2012) 1.61
Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol (2012) 1.60
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol (2012) 1.56
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl (2005) 1.54
Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol (2008) 1.49
Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch (2006) 1.48
Prognostic significance of patterns of seminal vesicle invasion in prostate cancer. Histopathology (2013) 1.46
Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res (2006) 1.46
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res (2008) 1.42
Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr (2007) 1.40
Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis. Am J Clin Pathol (2008) 1.39
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A (2009) 1.35
Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate (2004) 1.31
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate (2002) 1.30
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology (2009) 1.29
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2007) 1.27
FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J Pathol (2009) 1.27
The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch (2006) 1.25
Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer (2013) 1.25
Label-free electrochemical detection for aptamer-based array electrodes. Anal Chem (2005) 1.23
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol (2010) 1.22
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol (2010) 1.22
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res (2002) 1.21
Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol (2010) 1.19
Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res (2003) 1.18
Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate (2005) 1.18
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008) 1.17
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol (2013) 1.17
Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol (2013) 1.15
Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One (2012) 1.15
Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res (2010) 1.15
Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One (2012) 1.14
Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology (2011) 1.14
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol (2006) 1.13
The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol (2012) 1.12
Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.11
Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med (2009) 1.10
Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev (2008) 1.10
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol (2010) 1.09
Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol (2008) 1.09
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One (2010) 1.08
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res (2014) 1.08
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol (2010) 1.07
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem Biophys Res Commun (2011) 1.06
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res (2007) 1.06
Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One (2013) 1.06
Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res (2004) 1.05
Contemporary grading for prostate cancer: implications for patient care. Eur Urol (2012) 1.03
Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl (2005) 1.03
Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol (2011) 1.03
TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. Cancer Epidemiol (2012) 1.02
LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer (2011) 1.01
Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol Cell Biol (2006) 1.01
Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res (2005) 1.01
Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer (2010) 1.01
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood (2011) 1.01
Mice lacking asparaginyl endopeptidase develop disorders resembling hemophagocytic syndrome. Proc Natl Acad Sci U S A (2008) 1.01
Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol (2011) 1.01
Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl (2005) 1.01
Chromatin remodeling: recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J (2009) 1.00
Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res (2013) 1.00
Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol (2005) 1.00
Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch (2003) 1.00
Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer (2002) 1.00
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol (2014) 1.00
Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer (2009) 0.99
Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state formulation stability. J Pharm Sci (2007) 0.99
Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J Pharm Sci (2010) 0.99
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS (2008) 0.99
The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. Histopathology (2013) 0.99
Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch (2009) 0.99
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer (2014) 0.99
Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate (2002) 0.99
Solitary fibrous tumor of the prostate: a report of two cases. Pathol Int (2011) 0.98
Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate (2005) 0.97
SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J Natl Cancer Inst (2013) 0.96